While BRAF/MEK inhibitors or immune checkpoint inhibitors (ICI) have revolutionized the treatment of patients with metastatic melanoma, approximately 50% of patients still experience fatal outcomes. The gene discussed is MAP2K7; the disease is metastatic melanoma.